TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

Chunhai Hao, Jin H. Song, Belinda Hsi, Jamie Lewis, Doyoun K. Song, Kenneth C. Petruk, David L J Tyrrell, Norman M. Kneteman

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Tumor necrosis factor (TNF) family ligand TNF-α and Fas ligand (FasL) can trigger apoptosis in solid tumors, but their clinical usage has been limited by hepatotoxicity. TNF-related apoptosis-inducing ligand (TRAIL) is a newly identified member of the TNF family, and its clinical 1 application currently is under a similar debate. Here, we report a recombinant soluble form of human TRAIL (114 to 281 amino acids) that ; induces apoptosis in tumor cells but not human hepatocytes. We first isolated human hepatocytes from patients and showed that the human hepatocytes expressed Fas but no TRAIL death receptor DR4 and little DR5 on the cell surface. Antibody cross-linked FasL, but not TRAIL, triggered apoptosis of the human hepatocytes through cleavage of caspases. We then examined TRAIL hepatotoxicity in severe combined immunodeficient/Alb-uPA chimeric mice harboring human hepatocytes. Intravenous injection of FasL, but not TRAIL, caused apoptotic death of human hepatocytes within the chimeric liver, thus killing the mice. Finally, we showed that repeated intraperitoneal injections of TRAIL inhibited intraperitoneal and subcutaneous tumor growth without inducing apoptosis in human hepatocytes in these chimeric mice. The results indicate that the recombinant soluble human TRAIL has a profound apoptotic effect on tumor cells but is nontoxic to human hepatocytes in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)8502-8506
Number of pages5
JournalCancer Research
Volume64
Issue number23
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Hepatocytes
Growth
Neoplasms
Fas Ligand Protein
Apoptosis
Tumor Necrosis Factor-alpha
TNF-Related Apoptosis-Inducing Ligand Receptors
Ligands
Death Domain Receptors
Caspases
Intraperitoneal Injections
Intravenous Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hao, C., Song, J. H., Hsi, B., Lewis, J., Song, D. K., Petruk, K. C., ... Kneteman, N. M. (2004). TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Research, 64(23), 8502-8506. https://doi.org/10.1158/0008-5472.CAN-04-2599

TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. / Hao, Chunhai; Song, Jin H.; Hsi, Belinda; Lewis, Jamie; Song, Doyoun K.; Petruk, Kenneth C.; Tyrrell, David L J; Kneteman, Norman M.

In: Cancer Research, Vol. 64, No. 23, 01.12.2004, p. 8502-8506.

Research output: Contribution to journalArticle

Hao, C, Song, JH, Hsi, B, Lewis, J, Song, DK, Petruk, KC, Tyrrell, DLJ & Kneteman, NM 2004, 'TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice', Cancer Research, vol. 64, no. 23, pp. 8502-8506. https://doi.org/10.1158/0008-5472.CAN-04-2599
Hao, Chunhai ; Song, Jin H. ; Hsi, Belinda ; Lewis, Jamie ; Song, Doyoun K. ; Petruk, Kenneth C. ; Tyrrell, David L J ; Kneteman, Norman M. / TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. In: Cancer Research. 2004 ; Vol. 64, No. 23. pp. 8502-8506.
@article{ffdb3b7196644ff79f1911614ac1595d,
title = "TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice",
abstract = "Tumor necrosis factor (TNF) family ligand TNF-α and Fas ligand (FasL) can trigger apoptosis in solid tumors, but their clinical usage has been limited by hepatotoxicity. TNF-related apoptosis-inducing ligand (TRAIL) is a newly identified member of the TNF family, and its clinical 1 application currently is under a similar debate. Here, we report a recombinant soluble form of human TRAIL (114 to 281 amino acids) that ; induces apoptosis in tumor cells but not human hepatocytes. We first isolated human hepatocytes from patients and showed that the human hepatocytes expressed Fas but no TRAIL death receptor DR4 and little DR5 on the cell surface. Antibody cross-linked FasL, but not TRAIL, triggered apoptosis of the human hepatocytes through cleavage of caspases. We then examined TRAIL hepatotoxicity in severe combined immunodeficient/Alb-uPA chimeric mice harboring human hepatocytes. Intravenous injection of FasL, but not TRAIL, caused apoptotic death of human hepatocytes within the chimeric liver, thus killing the mice. Finally, we showed that repeated intraperitoneal injections of TRAIL inhibited intraperitoneal and subcutaneous tumor growth without inducing apoptosis in human hepatocytes in these chimeric mice. The results indicate that the recombinant soluble human TRAIL has a profound apoptotic effect on tumor cells but is nontoxic to human hepatocytes in vitro and in vivo.",
author = "Chunhai Hao and Song, {Jin H.} and Belinda Hsi and Jamie Lewis and Song, {Doyoun K.} and Petruk, {Kenneth C.} and Tyrrell, {David L J} and Kneteman, {Norman M.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-04-2599",
language = "English (US)",
volume = "64",
pages = "8502--8506",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

AU - Hao, Chunhai

AU - Song, Jin H.

AU - Hsi, Belinda

AU - Lewis, Jamie

AU - Song, Doyoun K.

AU - Petruk, Kenneth C.

AU - Tyrrell, David L J

AU - Kneteman, Norman M.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Tumor necrosis factor (TNF) family ligand TNF-α and Fas ligand (FasL) can trigger apoptosis in solid tumors, but their clinical usage has been limited by hepatotoxicity. TNF-related apoptosis-inducing ligand (TRAIL) is a newly identified member of the TNF family, and its clinical 1 application currently is under a similar debate. Here, we report a recombinant soluble form of human TRAIL (114 to 281 amino acids) that ; induces apoptosis in tumor cells but not human hepatocytes. We first isolated human hepatocytes from patients and showed that the human hepatocytes expressed Fas but no TRAIL death receptor DR4 and little DR5 on the cell surface. Antibody cross-linked FasL, but not TRAIL, triggered apoptosis of the human hepatocytes through cleavage of caspases. We then examined TRAIL hepatotoxicity in severe combined immunodeficient/Alb-uPA chimeric mice harboring human hepatocytes. Intravenous injection of FasL, but not TRAIL, caused apoptotic death of human hepatocytes within the chimeric liver, thus killing the mice. Finally, we showed that repeated intraperitoneal injections of TRAIL inhibited intraperitoneal and subcutaneous tumor growth without inducing apoptosis in human hepatocytes in these chimeric mice. The results indicate that the recombinant soluble human TRAIL has a profound apoptotic effect on tumor cells but is nontoxic to human hepatocytes in vitro and in vivo.

AB - Tumor necrosis factor (TNF) family ligand TNF-α and Fas ligand (FasL) can trigger apoptosis in solid tumors, but their clinical usage has been limited by hepatotoxicity. TNF-related apoptosis-inducing ligand (TRAIL) is a newly identified member of the TNF family, and its clinical 1 application currently is under a similar debate. Here, we report a recombinant soluble form of human TRAIL (114 to 281 amino acids) that ; induces apoptosis in tumor cells but not human hepatocytes. We first isolated human hepatocytes from patients and showed that the human hepatocytes expressed Fas but no TRAIL death receptor DR4 and little DR5 on the cell surface. Antibody cross-linked FasL, but not TRAIL, triggered apoptosis of the human hepatocytes through cleavage of caspases. We then examined TRAIL hepatotoxicity in severe combined immunodeficient/Alb-uPA chimeric mice harboring human hepatocytes. Intravenous injection of FasL, but not TRAIL, caused apoptotic death of human hepatocytes within the chimeric liver, thus killing the mice. Finally, we showed that repeated intraperitoneal injections of TRAIL inhibited intraperitoneal and subcutaneous tumor growth without inducing apoptosis in human hepatocytes in these chimeric mice. The results indicate that the recombinant soluble human TRAIL has a profound apoptotic effect on tumor cells but is nontoxic to human hepatocytes in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=9244237679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244237679&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-2599

DO - 10.1158/0008-5472.CAN-04-2599

M3 - Article

C2 - 15574753

AN - SCOPUS:9244237679

VL - 64

SP - 8502

EP - 8506

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -